 Kazia Therapeutics Ltd ASX:KZA NASDAQ:KZIA FRA:NV9 will share new data from its ongoing phase II study of paxalisib in glioblastoma in a poster presentation at the prestigious American Association of Cancer Research AACR Annual Meeting being held virtually from April 10-15 and from May 17-21, 2021. The new pharmacokinetic PK data shows how long paxalisib remains in the human body and strongly supports 60-milligram once-daily dosing, confirming the companys planned administration schedule for commercial launch. 